Public report
Patent-Cliff Watchlist
U.S. small-molecule drugs flagged for near-term Orange Book patent expiry signals, ranked by expiry attractiveness and confidence.
This is a screening tool, not legal advice. Patent and exclusivity interpretation requires qualified legal review before commercial decisions are made. Data sourced from FDA Orange Book as of July 10, 2026.
Opportunity MatrixNear-term LOE × low patent complexity — bottom-left quadrant is most actionable
Hover any drug to see details — bottom-left is simplest portfolio entry window
CNS
Dermatology
Gastroenterology
Pain
Respiratory
Patent complexity and Clinical competition are scored 0–5 (more dots = higher). Lower complexity and lower competition generally indicate a cleaner generic entry window. Click column headers to sort.
| Active ingredient | Applicant | Patent expiry | Confidence | |||||
|---|---|---|---|---|---|---|---|---|
| VERDESO | Dermatology | DESONIDE | GENUS | 13mo | August 13, 2027 | High | ||
| JUXTAPID | — | LOMITAPIDE MESYLATE | CHIESI | 13mo | August 19, 2027 | Medium | ||
| EMEND | — | APREPITANT | MSD | 15mo | September 26, 2027 | High | ||
| CHLORHEXIDINE GLUCONATE | — | CHLORHEXIDINE GLUCONATE | SAGE PRODS | 15mo | October 2, 2027 | High | ||
| AMITIZA | — | LUBIPROSTONE | SUCAMPO PHARMA LLC | 16mo | October 25, 2027 | High | ||
| ORACEA | — | DOXYCYCLINE | GALDERMA LABS LP | 17mo | December 19, 2027 | High | ||
| GILENYA | — | FINGOLIMOD HYDROCHLORIDE | NOVARTIS | 18mo | December 25, 2027 | High | ||
| ALVESCO | Respiratory | CICLESONIDE | AZURITY | 19mo | February 1, 2028 | High | ||
| ZETONNA | Respiratory | CICLESONIDE | AZURITY | 19mo | February 1, 2028 | High | ||
| REVLIMID | — | LENALIDOMIDE | BRISTOL MYERS SQUIBB | 20mo | March 8, 2028 | High | ||
| CRESEMBA | — | ISAVUCONAZONIUM SULFATE | ASTELLAS | 20mo | March 14, 2028 | High | ||
| ZOLINZA | — | VORINOSTAT | MSD SUB MERCK | 20mo | March 18, 2028 | High | ||
| TROKENDI XR | — | TOPIRAMATE | SUPERNUS PHARMS | 21mo | April 4, 2028 | High | ||
| SORILUX | Dermatology | CALCIPOTRIENE | MAYNE PHARMA | 22mo | May 7, 2028 | High | ||
| FARYDAK | — | PANOBINOSTAT LACTATE | SECURA | 23mo | June 13, 2028 | High | ||
| OLUX E | Dermatology | CLOBETASOL PROPIONATE | PHARMOBEDIENT | 28mo | November 5, 2028 | High | ||
| ERIVEDGE | — | VISMODEGIB | GENENTECH | 29mo | December 15, 2028 | High | ||
| RYTARY | — | CARBIDOPA; LEVODOPA | IMPAX | 30mo | December 26, 2028 | High | ||
| ZIPSOR | — | DICLOFENAC POTASSIUM | COSETTE | 32mo | February 24, 2029 | High | ||
| FINACEA | Dermatology | AZELAIC ACID | LEO PHARMA AS | 32mo | February 28, 2029 | High | ||
| KOSELUGO | — | SELUMETINIB SULFATE | ASTRAZENECA | 33mo | March 26, 2029 | High | ||
| BRISDELLE | — | PAROXETINE MESYLATE | LEGACY | 33mo | April 6, 2029 | High | ||
| VERKAZIA | — | CYCLOSPORINE | HARROW EYE | 35mo | June 2, 2029 | High | ||
| QSYMIA | — | PHENTERMINE HYDROCHLORIDE; TOPIRAMATE | VIVUS LLC | 35mo | June 14, 2029 | High | ||
| ZOKINVY | — | LONAFARNIB | SENTYNL THERAPS INC | 37mo | July 26, 2029 | High | ||
| MYDAYIS | CNS | AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE | TAKEDA PHARMS USA | 38mo | August 24, 2029 | High | ||
| OLYSIO | — | SIMEPREVIR SODIUM | JANSSEN PRODS | 38mo | September 5, 2029 | Medium | ||
| XELPROS | — | LATANOPROST | SUN PHARM | 38mo | September 12, 2029 | High | ||
| NAMENDA XR | — | MEMANTINE HYDROCHLORIDE | ABBVIE | 39mo | September 24, 2029 | High | ||
| XALKORI | — | CRIZOTINIB | PF PRISM CV | 40mo | November 6, 2029 | High | ||
| EMBEDA | Pain | MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE | ALPHARMA PHARMS | 40mo | November 7, 2029 | High | ||
| NINLARO | — | IXAZOMIB CITRATE | TAKEDA PHARMS USA | 40mo | November 20, 2029 | High | ||
| NAMZARIC | — | DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE | ABBVIE | 41mo | December 5, 2029 | Medium | ||
| OFEV | — | NINTEDANIB ESYLATE | BOEHRINGER INGELHEIM | 41mo | December 7, 2029 | High | ||
| ZYCLARA | — | IMIQUIMOD | BAUSCH | 41mo | December 11, 2029 | High | ||
| ATROVENT HFA | Respiratory | IPRATROPIUM BROMIDE | BOEHRINGER INGELHEIM | 42mo | January 17, 2030 | High | ||
| ENTEREG | — | ALVIMOPAN | CUBIST PHARMS | 43mo | February 12, 2030 | High | ||
| FABIOR | Dermatology | TAZAROTENE | MAYNE PHARMA | 44mo | February 24, 2030 | High | ||
| VRAYLAR | — | CARIPRAZINE HYDROCHLORIDE | ABBVIE | 44mo | March 17, 2030 | High | ||
| VONJO | — | PACRITINIB CITRATE | SOBI | 45mo | March 25, 2030 | Medium | ||
| TIVORBEX | — | INDOMETHACIN | GENUS | 45mo | April 23, 2030 | High | ||
| ZORVOLEX | — | DICLOFENAC | ZYLA | 45mo | April 23, 2030 | High | ||
| APRISO | Gastroenterology | MESALAMINE | SALIX | 46mo | May 1, 2030 | High | ||
| SYMBICORT AEROSPHERE | Respiratory | BUDESONIDE; FORMOTEROL FUMARATE | ASTRAZENECA | 47mo | May 28, 2030 | High | ||
| AIRSUPRA | Respiratory | ALBUTEROL SULFATE; BUDESONIDE | ASTRAZENECA | 47mo | May 28, 2030 | High | ||
| ACUVUE THERAVISION WITH KETOTIFEN | — | KETOTIFEN FUMARATE | JOHNSON JOHNSON VISN | 48mo | June 27, 2030 | High |